Silvant Capital Management LLC Purchases 1,918 Shares of IDEXX Laboratories, Inc. $IDXX

Silvant Capital Management LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.3% during the 4th quarter, HoldingsChannel reports. The firm owned 13,035 shares of the company’s stock after acquiring an additional 1,918 shares during the period. Silvant Capital Management LLC’s holdings in IDEXX Laboratories were worth $8,819,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Beacon Investment Advisory Services Inc. raised its stake in IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares during the last quarter. NEOS Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 82.7% in the third quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after acquiring an additional 13,599 shares during the period. Procyon Advisors LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $1,966,000. Finally, Diversified Trust Co. grew its holdings in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.6%

Shares of NASDAQ IDXX opened at $570.00 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $44.96 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 3.07 and a beta of 1.56. The stock’s fifty day simple moving average is $563.07 and its two-hundred day simple moving average is $625.43. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IDXX. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.